# Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients

> **NCT02164006** · PHASE1 · COMPLETED · sponsor: **TG Therapeutics, Inc.** · enrollment: 16 (actual)

## Conditions studied

- Hodgkin's Lymphoma

## Interventions

- **DRUG:** TGR-1202 + brentuximab vedotin

## Key facts

- **NCT ID:** NCT02164006
- **Lead sponsor:** TG Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-11
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2019-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02164006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02164006, "Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT02164006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*